This CPB has been revised to state that leuprolide is considered (i) medically necessary to suppress onset of puberty in transgender adolescents if they meet WPATH criteria, and (ii) experimental and investigational for juvenile idiopathic arthritis, metromenorrhagia, poryhyria cutanea tarda, and testicular cancer.